Scientists in the U.K. report that a new precision drug that stops cancer from repairing its DNA has shown promise in an early-stage clinical trial, highlighting the potential of a new class of drugs known as ATR inhibitors.
The drug candidate, tested in humans for the first time, was shown to be well tolerated and stopped the growth of tumors in over half of patients treated, as described in a paper titled, “First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors,” that was recently published in Cancer Discovery.
